Back to Search Start Over

Treatment of small cell bronchogenic carcinoma with VM-26.

Authors :
Woods RL
Fox RM
Tattersall MH
Source :
Cancer treatment reports [Cancer Treat Rep] 1979 Nov-Dec; Vol. 63 (11-12), pp. 2011-3.
Publication Year :
1979

Abstract

VM-26 is active in small cell bronchogenic carcinoma even in patients resistant to previous chemotherapy. The overall response rate was 28%, with a response rate of 29% in patients resistant to previous chemotherapy. This response rate is similar to that obtained with other single agents including Adriamycin, vincristine, cyclophosphamide, and procarbazine. The mild subjective and objective toxic effects of the drug make it a potentially useful agent in the treatment of this tumor.

Subjects

Subjects :
Adult
Aged
Bone Marrow drug effects
Clinical Trials as Topic
Drug Resistance
Female
Heart Failure chemically induced
Humans
Male
Middle Aged
Remission, Spontaneous
Teniposide adverse effects
Carcinoma, Bronchogenic drug therapy
Carcinoma, Small Cell drug therapy
Lung Neoplasms drug therapy
Podophyllotoxin analogs & derivatives
Teniposide therapeutic use

Details

Language :
English
ISSN :
0361-5960
Volume :
63
Issue :
11-12
Database :
MEDLINE
Journal :
Cancer treatment reports
Publication Type :
Academic Journal
Accession number :
230897

Tools

Authors Abstract Subjects Details